Open Actively Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

About

Brief Summary

Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Note: Other inclusion and exclusion criteria may apply.

Join this Trial

Share:
Study Stats
Protocol No.
22-001362
Category
Brain Cancer
Contact
Emese Filka
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05484622
For detailed technical eligibility, visit ClinicalTrials.gov.